Newtyn Management LLC Has $5.93 Million Stock Position in GRAIL, Inc. $GRAL

Newtyn Management LLC decreased its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 41.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 232,297 shares of the company’s stock after selling 167,703 shares during the quarter. GRAIL comprises 0.9% of Newtyn Management LLC’s holdings, making the stock its 22nd largest holding. Newtyn Management LLC owned 0.66% of GRAIL worth $5,933,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of GRAL. Sessa Capital IM L.P. bought a new position in shares of GRAIL in the fourth quarter valued at $53,550,000. Jacobs Levy Equity Management Inc. bought a new position in shares of GRAIL in the fourth quarter valued at $18,209,000. Wealthquest Corp bought a new position in shares of GRAIL in the first quarter valued at $18,247,000. Bank of America Corp DE bought a new position in shares of GRAIL in the fourth quarter valued at $10,638,000. Finally, AQR Capital Management LLC lifted its stake in shares of GRAIL by 61.0% in the first quarter. AQR Capital Management LLC now owns 1,337,163 shares of the company’s stock valued at $33,991,000 after buying an additional 506,440 shares in the last quarter.

Insiders Place Their Bets

In other news, President Joshua J. Ofman sold 9,692 shares of the stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $52.00, for a total value of $503,984.00. Following the sale, the president directly owned 492,076 shares of the company’s stock, valued at approximately $25,587,952. This represents a 1.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Chun R. Ding sold 339,800 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $49.53, for a total transaction of $16,830,294.00. Following the completion of the sale, the insider directly owned 3,305,055 shares in the company, valued at approximately $163,699,374.15. The trade was a 9.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 361,694 shares of company stock worth $17,780,266 over the last quarter. 1.85% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group upped their target price on shares of GRAIL from $32.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, GRAIL currently has an average rating of “Hold” and an average price target of $31.50.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $33.59 on Friday. The company has a market capitalization of $1.21 billion, a P/E ratio of -2.56 and a beta of 3.18. GRAIL, Inc. has a fifty-two week low of $12.33 and a fifty-two week high of $63.99. The company’s 50-day moving average is $36.97 and its 200 day moving average is $35.88.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing the consensus estimate of ($3.14) by ($0.04). The firm had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. As a group, research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

GRAIL Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.